The global transplant diagnostic market was valued at USD 468.8 million in 2015. The rising investment in research and development (R&D) coupled with the continual introduction of technical advancements, has resulted in the generation of improved diagnostic tools, which is primarily driving the growth of the global market.
Increasing number of patients suffering from chronic diseases frequently leading to organ failure is creating the huge upsurge in the demand for transplant procedures. In addition, the adoption of stem cell therapy and personalized medicine is escalating. As a result, the demand for transplant diagnostics is increasing swiftly.
The risks and complexities associated with organ transplants necessitate the need for improved and sophisticated diagnostic tools. The Next Generation Sequencing (NGS) technology is rapidly replacing the traditional diagnostic methods, such as serological techniques employed in Human Leukocyte Antigen (HLA) typing, owing to the growing demand for high-throughput diagnostic tools with enhanced accuracy.
Presently a huge gap exists between the two events, organ donation by donors and organ reception by patients; in an attempt to bridge this gap several research and development efforts have been directed at developing alternatives, such as the xenotransplantation procedure, wherein organs or tissues of animal origin are transplanted into human recipients.
The market growth is expected to be restrained by factors such as reimbursement controversies and ethical issues in some parts of the world. Additionally, high costs in performing HLA matching using PCR and NGS devices are challenging the growth of the transplant diagnostic market in the developing countries.
Japan transplant diagnostic market, by Product, 2014 - 2024 (USD Million)
The global market is segmented into molecular assay and non-molecular assay segments on the basis of technology. The molecular assay segment captured the largest market share in 2015 owing to the expanding stem cell, solid organ, and soft tissue transplantation procedures. In addition, the rising adoption of HLA typing using sequencing-based molecular assays is fueling the growth of the molecular assay segment.
Manufacturers implement strategies such as long-term purchase contracts for reagents and consumables with diagnostic laboratories and clinics. In addition, the repeat purchase of these products results in revenue generation. As a result, the reagents and consumables segment accounted for the largest market share in 2015 and is expected to grow at the fastest CAGR during the forecast period.
Moreover, the software segment is expected to show significant growth during the forecast period. Factors, such as frequent technical advancements being introduced result in the increased availability of version upgrades with enhanced features suitable for the existing instruments, which is anticipated to propel the growth of the software market from 2016 to 2024.
North America dominated the global market in 2015 with a revenue share of38%. The major drivers of the market in North America include high adoption rate of the advanced techniques and diagnostic tools, higher healthcare expenditure, and the availability of skilled professionals.
Furthermore, government initiatives and research grants are encouraging the start of new clinical research and development projects in the region. Canadian R&D tax credit program is an example of one such government initiative boosting the R&D in the country. Government support in the form of funding and tax benefits is positively impacting the market. Considering all the above-mentioned factors, North America is projected to maintain its supremacy throughout the forecast period.
Asia-Pacific is estimated to show fastest CAGR of 10.7% from 2016 to 2024. Availability of skilled professionals, the presence of advanced healthcare infrastructure, and the increased accessibility to medical treatments at a lower cost is spurring the growth of the medical tourism industry in this region. In addition, a large population pool of diseased individuals with underlying genetic impairments is expected to fuel the demand for advanced medical treatments including transplants. Therefore, the booming medical tourism industry coupled with the large target population is estimated to drive the growth of the transplant diagnostics in the Asia Pacific region.
Furthermore, the rising adoption of stem cell therapy is anticipated to augment the demand for transplant diagnostics in the region. Thus, Asia Pacific is expected to dominate the overall market throughout the forecast period. The presence of a well-defined regulatory framework, a relatively high awareness level regarding organ donation, and the existence of advanced healthcare facilities are some of the factors that are anticipated to drive the transplant diagnostic market in India and Japan towards growth.
Competitive Market Share Insights
The global market for transplant diagnostics is highly competitive with very fewplayers competing with each other in the international market. The quality and accuracy constraints of the transplant diagnostic techniques like serology-based and PCR-based HLA typing increase the overall cost of the products. As a result, market players are implementing strategies, such as long-term contracts with diagnostic clinics and laboratories and discount pricing for bulk purchases.
The major market players in this market are Thermo Fisher Scientific, Inc., Illumina, Inc., F. Hoffmann La-Roche AG., Abbott Laboratories Inc., Qiagen N.V., Immucor Transplant Diagnostics, Inc., Bio-rad Laboratories, Inc., Affymetrix, Inc., and Omixon Ltd.
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.